微小核糖核酸作为新型生物标志物在HIV-1感染控制中的临床应用

Clinical implications of MicroRNAs as new biomarkers in HIV-1 infection control

微小核糖核酸(miRNAs),19～24bp的单链非编码RNA序列是信使核糖核酸(mRNA)翻译和转换的关键调节剂,最终导致mRNA翻译抑制或者降解。综述回顾了miRNAs在1型艾滋病病毒(HIV-1)感染与宿主的相互作用过程中所起的调节作用。HIV-1感染导致miRNAs的改变对艾滋病发病机制和疾病进展的影响。重点探讨了miRNAs潜在的临床应用,评估了作为新型生物标志物、参与构建核酸疫苗,进行临床抗病毒治疗等应用方面存在的问题和需要克服的困难。

MicroRNAs,small non-coding RNAs with size ranging from 19 to 24 nucleotides,are key mediators of regulating the gene expression at the post transcriptional level either through translation repression or mRNA degradation.In this paper,we review the findings pertaining to the field of miRNAs and HIV-1 interplay,and effect of miRNAs files changed in HIV-1-infection on AIDS pathogenesis and progression,including the potential of miRNAs being as novel infection biomarkers with emphasis on potential clinical applications,along with an evaluation of the challenges still to be overcome.